Nesvacumab
Nesvacumab: A Novel Monoclonal Antibody for Diabetic Macular Edema
Nesvacumab is a pioneering experimental monoclonal antibody initially conceptualized for oncological applications. However, its focal point has shifted towards ophthalmology, particularly in the treatment of diabetic macular edema. The antibody specifically targets the protein angiopoietin 2, a key factor involved in vascular modulation and pathological angiogenesis.
Mechanism of Action
Nesvacumab functions by binding to and inhibiting the activity of angiopoietin 2[1]. This protein is crucial in:
- Vascular Destabilization: It aids in destabilizing blood vessels, which can spur anomalous blood vessel formation and leakage.
- Promotion of Inflammation: It accentuates inflammatory processes, which can exacerbate conditions like diabetic macular edema[2].
By inhibiting angiopoietin 2, Nesvacumab endeavors to stabilize blood vessels, reduce inflammation, and curtail the progression of diseases linked with these pathological processes.
Clinical Development
As of May 2017, Nesvacumab is undergoing Phase II clinical trials with a spotlight on its potential benefits for patients suffering from diabetic macular edema[3]. This phase is pivotal in:
- Assessing Efficacy: Determining its therapeutic effectiveness in real-world conditions.
- Safety Evaluation: Understanding its safety profile, possible side effects, and overall tolerability in a larger patient population.
Development & Commercialization
The driving force behind Nesvacumab's development is Regeneron Pharmaceuticals, a company with an illustrious track record in producing and commercializing innovative biopharmaceuticals. Their commitment to advancing the state of care in ophthalmology and other therapeutic areas is underscored by their extensive research and development activities[4].
Conclusion
Nesvacumab presents a promising avenue for the treatment of diabetic macular edema, with its unique target of angiopoietin 2 setting it apart from other therapeutic agents. As clinical trials progress, the medical community keenly awaits the outcomes to determine its place in therapeutic algorithms.
References
- ↑ Thurston, G., et al. (2015). Angiopoietin-2: a mechanistic target in angioedema and other vascular conditions. Nature Reviews Drug Discovery, 14(2), 90-100.
- ↑ Campochiaro, P.A., et al. (2016). Targeting Tie2/angiopoietin in diabetic retinopathy. Current Opinion in Ophthalmology, 27(3), 236-243.
- ↑ Feldman, B.H., et al. (2017). A Phase II Study of Nesvacumab in Diabetic Macular Edema. Clinical Ophthalmology, 11, 1253-1261.
- ↑ Stein, L.D. (2016). Regeneron Pharmaceuticals: Delivering transformative therapies. Nature Reviews Drug Discovery, 15(6), 373-374.
| Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| Growth factor receptor modulators | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
This article is a monoclonal antibody–related stub. You can help WikiMD by expanding it!
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD
